试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Effects of Metformin and Fish Oil on Treatment With Clozapine
编号:NCT02140788登记状态:提前终止企业 / 申办者:Duke University
药物 / 成分:Metformin、Fish Oil
登记的停止原因(原文):PI left institution
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
CREON for the Treatment of Post-RYGB Hypoglycemia
编号:NCT02733848登记状态:提前终止企业 / 申办者:East Carolina University
药物 / 成分:Creon、Diet、Placebo
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery
编号:NCT03115151登记状态:提前终止企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Bupivacaine、Hydromorphone、Fentanyl
登记的停止原因(原文):The surgical team has difficulty to find level 1 and 2 fusions for the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Evaluation of Testosterone Nasal Gel in Hypogonadal Boys
编号:NCT03345797登记状态:提前终止企业 / 申办者:Acerus Biopharma Inc.
药物 / 成分:Testosterone Nasal Gel [Natesto]
登记的停止原因(原文):Lack of patients and commercial reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
编号:NCT03649841登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Antiandrogen Therapy、Abiraterone Acetate、Prednisone、Radiation Therapy
登记的停止原因(原文):Terminated due to low accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
编号:NCT03728933登记状态:提前终止企业 / 申办者:UCB Biopharma SRL
药物 / 成分:Rotigotine 1 milligram/24 hours、Rotigotine 2 milligram/24 hours、Placebo
登记的停止原因(原文):Sponsor decision; Not a safety decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
编号:NCT04023071登记状态:提前终止企业 / 申办者:Fate Therapeutics
药物 / 成分:FT516、Rituximab、Obinutuzumab、Cyclophosphamide
登记的停止原因(原文):The study was terminated by the Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
编号:NCT04245722登记状态:提前终止企业 / 申办者:Fate Therapeutics
药物 / 成分:FT596、Cyclophosphamide、Fludarabine、Rituximab
登记的停止原因(原文):The study was terminated by the Sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures
编号:NCT04320940登记状态:提前终止企业 / 申办者:NEMA Research, Inc.
药物 / 成分:Phenobarbital Sodium Injection
登记的停止原因(原文):Insufficient participant recruitment hindered the study's progress, preventing robust data collection and compromising statistical power
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-26
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
编号:NCT05329545登记状态:提前终止企业 / 申办者:Mersana Therapeutics
药物 / 成分:Upifitimab rilsodotin、Placebo
登记的停止原因(原文):Study Terminated by Sponsor
查看官方原始记录 ↗